{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:28Z","timestamp":1792453468206,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vhri.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T18:31:59Z","timestamp":1629484319000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity\u2013Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia"],"prefix":"10.1016","volume":"25","author":[{"given":"Saeed","family":"Bohlega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elboghdady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awatef","family":"Al-Johani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshu","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdoline Khalil","family":"Mughari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Al-Saqa\u2019aby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omneya","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Alarieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9648","key":"10.1016\/j.vhri.2021.03.007_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2021.03.007_bib2","first-page":"ii37","article-title":"Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?","volume":"51","author":"Nathwani","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.vhri.2021.03.007_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000431042","article-title":"Multiple sclerosis epidemiology in Middle East and north Africa: A systematic review and meta-analysis","volume":"44","author":"Heydarpour","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"5","key":"10.1016\/j.vhri.2021.03.007_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1352458513504328","article-title":"Increasing prevalence and incidence rates of multiple sclerosis in Kuwait [published correction appears in Mult Scler. 2017;23(9):NP1]","volume":"20","author":"Alroughani","year":"2014","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.vhri.2021.03.007_bib5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1352458512459291","article-title":"Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar","volume":"19","author":"Deleu","year":"2013","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.vhri.2021.03.007_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00207454.2011.565893","article-title":"Prevalence of multiple sclerosis in Dubai, United Arab Emirates","volume":"121","author":"Inshasi","year":"2011","journal-title":"Int J Neurosci"},{"issue":"2","key":"10.1016\/j.vhri.2021.03.007_bib7","first-page":"85","article-title":"The need for a multiple sclerosis registry in the Gulf region","volume":"19","author":"Alroughani","year":"2014","journal-title":"Neurosciences (Riyadh, Saudi Arabia)"},{"issue":"3","key":"10.1016\/j.vhri.2021.03.007_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.vhri.2021.03.007_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.smim.2009.08.003","article-title":"Genetics and pathogenesis of multiple sclerosis","volume":"21","author":"Zuvich","year":"2009","journal-title":"Semin Immunol"},{"issue":"7","key":"10.1016\/j.vhri.2021.03.007_bib10","first-page":"676","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"8","key":"10.1016\/j.vhri.2021.03.007_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","article-title":"Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis","volume":"31","author":"Thom","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.vhri.2021.03.007_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/03007995.2018.1476334","article-title":"Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview","volume":"35","author":"Deleu","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vhri.2021.03.007_bib14","series-title":"Merck KGaA Mavenclad (Cladrabine) [package insert]","year":"1993"},{"issue":"4","key":"10.1016\/j.vhri.2021.03.007_bib15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics J Am Soc Exp Neurotherapeutics"},{"key":"10.1016\/j.vhri.2021.03.007_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"10.1016\/j.vhri.2021.03.007_bib17","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2017","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.vhri.2021.03.007_bib18","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.vhri.2021.03.007_bib19","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the Oracle-MS study","volume":"3","author":"Freedman","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.vhri.2021.03.007_bib20","unstructured":"Ayati N, Fleifel L, Sharifi S, Sahraian MA, Nikfar S. Cladribine tablets are a cost-effective and cost-saving treatment strategy for high disease activity relapsing multiple sclerosis patients in Iran. Mult Scler Relat Disord. In press"},{"key":"10.1016\/j.vhri.2021.03.007_bib21","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1016\/j.jval.2019.09.1823","article-title":"PND53 economic evaluation of cladribine tablets in relapsing multiple sclerosis (RMS) patients with high disease activity (HDA) in Lebanon","volume":"22","author":"Metni","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2021.03.007_bib22","doi-asserted-by":"crossref","first-page":"A652","DOI":"10.1016\/j.jval.2016.09.1756","article-title":"Cost-effectiveness of apixaban for the treatment of atrial fibrillation patients in the Kingdom of Saudi Arabia","volume":"19","author":"Osenenko","year":"2016","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.vhri.2021.03.007_bib24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.vhri.2021.03.007_bib25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.vhri.2021.03.007_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkm210","article-title":"Outpatient parenteral Antimicrobial Therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years","volume":"60","author":"Matthews","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.vhri.2021.03.007_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","article-title":"Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: A retrospective real-world study","volume":"6","author":"Anastasio","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"5","key":"10.1016\/j.vhri.2021.03.007_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","article-title":"Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population","volume":"12","author":"Tappenden","year":"2009","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.vhri.2021.03.007_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator","volume":"14","author":"Palace","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.vhri.2021.03.007_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004073","article-title":"UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model","volume":"4","author":"Palace","year":"2014","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.vhri.2021.03.007_bib33","first-page":"1508","article-title":"Mortality of patients with multiple sclerosis: a cohort study in UK primary care","volume":"261","author":"Jick","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"10.1016\/j.vhri.2021.03.007_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.41.8.1193","article-title":"Cause of death in patients attending multiple sclerosis clinics","volume":"41","author":"Sadovnick","year":"1991","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.vhri.2021.03.007_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"4","key":"10.1016\/j.vhri.2021.03.007_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.vhri.2021.03.007_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.vhri.2021.03.007_bib38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10198-015-0728-3","article-title":"Multiple sclerosis: relapses, resource use, and costs","volume":"17","author":"Hawton","year":"2016","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"2","key":"10.1016\/j.vhri.2021.03.007_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:30Z","timestamp":1761941550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"alternative-id":["S2212109921000790"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2021.03.007","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity\u2013Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of ISPOR--The professional society for health economics and outcomes research.","name":"copyright","label":"Copyright"}]}}